Overview

This four-panel antibody test simultaneously screens for HIV, hepatitis C, syphilis (Treponema pallidum) and hepatitis B from a single sample, a configuration that suits high-throughput screening programmes. For B2B buyers the procurement question is consistency: every lot must perform to the same specification so that a positive or negative result means the same thing across shipments.

How It Works

Sourcing begins with confirming the device holds in-vitro diagnostic registration for the intended market and that the manufacturer can supply lot-specific performance data. Because the panel bundles four assays, a weak lot in any one line undermines the whole cassette, so require a certificate of analysis covering all four targets. Standardise on one manufacturer and one catalogue number to avoid silent product changes between orders.

Indications

The test is used for preliminary antibody screening in clinical, occupational-health and outreach settings. It is a screening tool, not a confirmatory diagnosis; reactive results require follow-up testing. B2B demand comes from hospitals, laboratories, NGOs and occupational-health programmes that need a single, efficient panel for routine serology.

Dosage & Administration

There is no dosage. The decisive parameters are sample type, read time and storage condition. Procurement should specify the accepted specimen (serum, plasma or whole blood), the result window, and the labelled shelf life. Define acceptance criteria for a lot: sensitivity and specificity figures, and a clear invalid-rate threshold below which a shipment is rejected.

Storage & Sourcing

Most rapid cassettes store at cool, dry room temperature, though some reagents prefer a controlled cold window, so follow the labelled range and avoid freeze-thaw. For B2B sourcing, demand sealed foil pouches with desiccant, legible batch and expiry, and a supplier quality agreement covering recalls. Confirm the cold or ambient chain was maintained during transit and that stock is rotated to first-expiry-first-out.

FAQ

Q: What documentation proves the panel is compliant?

In-vitro diagnostic registration for the target market plus a per-lot certificate of analysis covering all four antibodies, with stated sensitivity and specificity.

Q: Why insist on one manufacturer and catalogue number?

Because the four assays are integrated, a silent reformulation between orders can shift performance. Fixed sourcing keeps lot-to-lot behaviour predictable.

Q: Does a positive result need confirmation?

Yes. This is a screening panel; reactive findings must be confirmed by specific follow-up testing before any clinical conclusion is drawn.

Q: How should storage protect batch consistency?

Keep cassettes in sealed foil with desiccant at the labelled temperature, rotate stock first-expiry-first-out, and verify the transport chain was unbroken.